Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey

Fig. 2

Current use of LTP. a Duration of current LTP use (among n = 151 patients currently using LTP). Patients were asked “How long have you been taking a medication on a long-term (regular, ongoing) basis TO PREVENT angioedema attacks from happening?” b Type of LTP currently used (n = 151). Patients may have chosen more than one. Patients were asked “Which of the following medications do you currently take on a long-term (regular, ongoing) basis TO PREVENT angioedema attacks from happening? Select all that apply.” C1-INH includes Berinert® and Cinryze®; androgens include danazol, Winstrol®; and Oxandrin®; and tranexamic acid includes tranexamic acid and Lysteda®. Patients were able to enter free text under “other”; the most frequently listed medications included Firazyr® and Exacyl®. c Proportion of patients currently using LTP stratified by number of attacks in the last 6 months. C1-INH C1 inhibitor, LTP long-term prophylaxis

Back to article page